Revvity Inc. Stock (US76155R1086): Analyst Views and Valuation Put Healthcare Name in Focus

Revvity shares trade below their 52-week high while Wall Street remains split between Hold and Buy, leaving valuation and growth prospects in focus for US healthcare investors.

Responsible: ad hoc news Markets & Valuation Desk. Reviewed prior to publication on June 15, 2026 at 10:31 PM ET. Details in the imprint.

Revvity Inc. trades on the New York Stock Exchange under the ticker symbol RVTY, giving US investors exposure to a mid-cap life science and diagnostics player carved out of the former PerkinElmer business. As of June 14, 2026, Revvity shares closed around $99 on the NYSE, leaving the stock well off its 52-week high above $118 but also above its 52-week low near $79. That price range, coupled with mixed analyst opinions and a forward-looking growth story in diagnostics and life sciences tools, keeps the stock squarely in focus for valuation-oriented investors. With no major fresh earnings or deal announcements on the tape in recent days, the discussion around Revvity currently centers on how its fundamentals and analyst views line up against its trading multiples.

How Wall Street currently rates Revvity

Revvity emerged as a standalone brand in 2023 after PerkinElmer completed the sale of its applied, food and enterprise services businesses and rebranded the remaining life-science and diagnostics operations as Revvity Inc. That restructuring left the company positioned squarely in higher-growth segments like reproductive health, genomics, immunodiagnostics and pharma services, which many covering analysts see as attractive end markets. According to recent consensus data compiled by several broker and financial-data platforms, Wall Street sentiment on Revvity is broadly constructive but not euphoric, with a tilted mix toward Hold and Buy ratings. Some services show the average recommendation clustering around a moderate buy category, while others show a more neutral stance, underscoring that analysts differ on how quickly Revvity can translate its portfolio into sustained double-digit growth.

Price targets published over the past few months typically imply upside from the current trading level, but the spread is relatively wide, reflecting both execution risk and differing assumptions for margins. On the bullish end, analysts highlighting Revvity's exposure to advanced diagnostics, genomic testing and specialty reagents argue that the company can benefit from secular demand in precision medicine and biopharma R&D, particularly if macro headwinds in lab spending ease. More cautious analysts emphasize that Revvity still needs to prove that the streamlined portfolio and ongoing integration work can consistently deliver mid-teens adjusted earnings-per-share growth, and they highlight sensitivity to capital-spending cycles in pharma and academic research budgets. The tension between those two views feeds directly into how valuation metrics are interpreted.

From a near-term rating perspective, some brokers have trimmed their price objectives in recent quarters as they recalibrated models for slower instrument demand and higher financing costs across the sector. At the same time, the absence of large negative estimate revisions in the latest quarter suggests the Street largely views recent operational trends as manageable rather than thesis-breaking. That combination of moderated targets but relatively stable earnings estimates is typical for a company moving from a transformation phase into what investors hope will be a more normalized growth trajectory. For now, analyst reports generally point to execution on cost discipline, integration and targeted R&D investments as the main levers Revvity can use to earn a higher market multiple over time.

Where Revvity's valuation stands versus growth expectations

At roughly $99 per share and based on consensus earnings expectations, Revvity trades at a forward price-to-earnings multiple that places it below premium high-growth diagnostics names but above slower-growing diversified industrials. Some valuation screens classify Revvity as moderately valued within the US healthcare tools and diagnostics universe, particularly when its expected earnings growth and cash generation are taken into account. In addition to P/E, investors also look at enterprise-value-to-EBITDA and price-to-sales ratios, which show Revvity at a discount to a handful of faster-growing life science peers but at a premium to more cyclical or lower-margin names. For investors who focus on growth-adjusted valuation metrics such as PEG ratios, Revvity typically lands in a middle ground: not the cheapest stock in the group, but not priced like a hyper-growth story either.

Cash flow and balance-sheet metrics are key to that discussion. Recent company filings and commentary have highlighted Revvity's focus on improving free cash flow conversion as restructuring costs fade and integration synergies materialize. A stronger cash profile would give the company more flexibility to invest in higher-return R&D projects, pursue bolt-on acquisitions in areas like niche diagnostics and reagents, or step up capital returns through buybacks. While Revvity does not currently stand out as a high-dividend payer among US healthcare stocks, its ability to generate consistent cash could still matter for valuation, particularly if management prioritizes shareholder-friendly capital allocation once the bulk of transformation spending is behind it.

Another factor for valuation is Revvity's margin profile. Historically, parts of the legacy PerkinElmer portfolio carried industrial and services characteristics that weighed on consolidated margins relative to pure-play diagnostics or life science tools peers. The reconfigured Revvity aims to feature a higher mix of consumables, assays and software-enabled offerings, which tend to carry better margins and more recurring revenue. If the company can demonstrate sustained improvement in adjusted operating margins over the next few reporting periods, some analysts argue that the current valuation could leave room for multiple expansion. Conversely, if margins stall or pricing pressure in diagnostics intensifies, the market could continue to treat Revvity as a value-oriented healthcare name rather than a premium growth franchise.

Technical indicators published by charting platforms show that Revvity's stock has recently traded in a multi-month range, with resistance near its 52-week high and support closer to the high-$70s to low-$80s band. Daily technical summaries in some tools point to a cautious reading, with some short-term indicators flagging selling pressure, while medium-term gauges remain more balanced. Those readings can shift quickly, but they reinforce the impression from fundamentals and analyst commentary: Revvity is not currently treated as a momentum stock, but rather as a name where valuation, balance-sheet strength and execution on its focused diagnostics strategy will be decisive.

Revvity's position in key benchmarks also influences how US investors view the name. The company is listed on the NYSE and appears in a range of healthcare and mid-cap indices tracked by institutional investors, though it is not among the mega-cap constituents of the Dow Jones Industrial Average or the largest weights in the S&P 500. This index presence helps give the stock a baseline of liquidity and passive-ownership support, but it also means Revvity can be sensitive to broader factor rotations between growth and value, or between defensive healthcare and cyclical sectors. For fundamental investors, those flows can create windows where the stock trades away from its perceived intrinsic value, depending on prevailing risk sentiment.

On the corporate side, management has continued to emphasize Revvity's strategic focus on three main pillars: advanced diagnostics, life science research solutions and pharma services. The diagnostics segment includes newborn screening, reproductive health and infectious disease testing, while research solutions and services provide instruments, reagents and contract services to pharmaceutical and biotech customers. Each of these franchises taps into structurally growing markets, though the pace of that growth can be moderated in the short term by budget cycles, regulatory changes or macroeconomic conditions. Strategically, Revvity's ability to cross-sell across those platforms and deepen relationships with health systems and biopharma clients is central to the long-term equity story that many valuation-focused investors are attempting to underwrite.

From a risk perspective, Revvity shares several common exposures with other US-listed healthcare tools and diagnostics names. Regulatory oversight of diagnostic products, reimbursement decisions for testing services and procurement behavior in public health programs can all affect demand and pricing. In addition, competition from large diversified players as well as smaller specialized companies means Revvity must continually invest in innovation to defend and grow share in its core markets. Those competitive dynamics feed back into investor discussions about how much of a premium, if any, the market should assign to the company's earnings profile. For valuation-conscious investors weighing entry or exit points, such factors often matter as much as headline multiples.

Against this backdrop, Revvity remains a name that sits between pure value and high-growth narratives in the US healthcare universe, with fundamentals, analyst sentiment and technicals each sending a nuanced signal. Investors watching the stock may pay particular attention in coming quarters to how management delivers on its margin and cash-flow ambitions and whether the company can demonstrate that its focused portfolio can support a sustainably higher growth rate than the broader tools and diagnostics group.

Revvity in a nutshell for US investors

• Name: Revvity Inc.
• Industry: Life science tools and diagnostics
• Headquarters: Waltham, Massachusetts, United States
• Core markets: Advanced diagnostics, life science research, pharma and biotech services
• Revenue drivers: Diagnostic assays and screening, instruments and reagents for research, laboratory and pharma services
• Listing: New York Stock Exchange, ticker RVTY
• Trading currency: US dollars (USD)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.